AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16766775 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit-vegetable intervention
Number of subjects: 122
Study 16766775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination high FV, low-fat intervention
Number of subjects: 122
Study 16766775 — intervention group
Group type: COMPARATOR
Intervention: Low-fat intervention
Number of subjects: 122
Study 15528909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sodium fluoride dentifrice (2,800 ppm F, high-NaF)
Number of subjects: 955
Study 15528909 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental 0.454% stabilized stannous fluoride with sodium hexametaphosphate dentifrice (SnF2-HMP)
Number of subjects: 955
Study 15528909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium fluoride dentifrice (500 ppm F, low-NaF)
Number of subjects: 955
Study 15528909 — intervention group
Group type: COMPARATOR
Intervention: Standard 1,100 ppm F sodium fluoride positive control dentifrice
Number of subjects: 955
Study 11731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model
Number of subjects: 2016
Study 11731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 2016
Study 11731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant analysis model
Number of subjects: 2016
Study 11731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biochemical variables
Number of subjects: 2016
Study 9563865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (initial bolus 0.1 mg kg(‐1) then 1 mg kg(‐1)h(‐1))
Number of subjects: 10
Study 9563865 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (initial bolus 0.11 mg kg(‐1) then 14 microg kg(‐1)h(‐1))
Number of subjects: 10
Study 9563865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7946936 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20
Study 7946936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3429174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) glucagon
Number of subjects: 435
Study 3429174 — intervention group
Group type: COMPARATOR
Intervention: No glucagon (Control)
Number of subjects: 435
Study 28462577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lode Excalibur Sport
Number of subjects: 8
Study 28462577 — intervention group
Group type: COMPARATOR
Intervention: Tacx i-Magic
Number of subjects: 8
Study 26988811 — intervention group
Group type: COMPARATOR
Intervention: CTA
Number of subjects: 656
Study 26988811 — intervention group
Group type: COMPARATOR
Intervention: CTP+CTA
Number of subjects: 656
Study 26988811 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT
Number of subjects: 656
Study 25196321 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil in the morning and at noon over 3 weeks
Number of subjects: 33
Study 25196321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25196321 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 33
Study 23496025 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 15
Study 21832304 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P (carbohydrate with protein)
Number of subjects: 10
Study 21832304 — intervention group
Group type: COMPARATOR
Intervention: C (carbohydrate without protein)
Number of subjects: 10
Study 17603048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg once daily with brief lifestyle modification
Number of subjects: 42
Study 17603048 — intervention group
Group type: COMPARATOR
Intervention: Placebo with brief lifestyle modification
Number of subjects: 42
Study 17603048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 42
Study 17115902 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV therapy
Number of subjects: 0
Study 12663719 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin 130 mg/m² day 1 plus capecitabine 2,000 mg/m²/d days 1 to 14 every 3 weeks (arm A)
Number of subjects: 89
Study 12663719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m² days 1 and 14 combined with capecitabine 3,500 mg/m² days 1 to 7 and 14 to 21 every 4 weeks (arm B)
Number of subjects: 89
Study 11045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips HP555 electric toothbrush
Number of subjects: 50
Study 11045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips HP510 electric toothbrush
Number of subjects: 50
Study 11045370 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Jordan V‐shaped, medium)
Number of subjects: 50
Study 9005676 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-suction drainage
Number of subjects: 44
Study 9005676 — intervention group
Group type: COMPARATOR
Intervention: Redon-suction drainage
Number of subjects: 44
Study 2148333 — intervention group
Group type: EXPERIMENTAL
Intervention: Total night's sleep deprivation (TSD) under 'conventional' conditions
Number of subjects: 30
Study 2148333 — intervention group
Group type: COMPARATOR
Intervention: Total night's sleep deprivation (TSD) with patients kept in bed and not permitted to sleep
Number of subjects: 30
Study 7417369 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (30% energy from fat, 1/3 PUFA)
Number of subjects: 60
Study 7417369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20 energy % PUFA)
Number of subjects: 60
Study 7417369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40 energy % fat, 19 energy % PUFA)
Number of subjects: 60
Study 7417369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40 energy % fat, 3 energy % PUFA)
Number of subjects: 60
Study 31909703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Number of subjects: 16
Study 31909703 — intervention group
Group type: COMPARATOR
Intervention: Typical physical therapy (Control)
Number of subjects: 16
Study 31655054 — intervention group
Group type: EXPERIMENTAL
Intervention: A-index nomogram
Number of subjects: 672
Study 31226660 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal intragastric infusion of 2.5 g lauric acid
Number of subjects: 12
Study 31226660 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotion induction
Number of subjects: 12
Study 31226660 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 26859547 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 μg/kg dexmedetomidine (small dose)
Number of subjects: 134
Study 26859547 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 μg/kg dexmedetomidine (medium dose)
Number of subjects: 134
Study 26859547 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (vehicle control)
Number of subjects: 134
Study 25305352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α,25-dihydroxyvitamin D3 (1,25(OH)2D)
Number of subjects: 0
Study 24078278 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-3031 (1.8, 3.6, 6, or 18 mg)
Number of subjects: 48
Study 24078278 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-3031 (3.6 to 6 mg)
Number of subjects: 48
Study 24078278 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (100 μg/m² daily for 5 days)
Number of subjects: 48
Study 24078278 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-3031 and Filgrastim
Number of subjects: 48
Study 21775759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling intervention
Number of subjects: 925
Study 21775759 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 925
Study 19420402 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-week physical activity program
Number of subjects: 16
Study 17012110 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF levels in PCOS patients
Number of subjects: 52
Study 17012110 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bFGF levels in PCOS patients
Number of subjects: 52
Study 17012110 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid VEGF and bFGF levels in PCOS patients
Number of subjects: 52
Study 17012110 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum bFGF levels with FSH administration
Number of subjects: 52
Study 17012110 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of follicular fluid bFGF concentrations with mature oocytes
Number of subjects: 52
Study 12507525 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention 'Underage Drinking: A Roll of the Dice' with accompanying discussion guide.
Number of subjects: 300
Study 12507525 — intervention group
Group type: COMPARATOR
Intervention: Video intervention 'Underage Drinking: A Roll of the Dice' with follow-up materials.
Number of subjects: 300
Study 10981170 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil (angiotensin receptor blocker)
Number of subjects: 1000
Study 10981170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9387947 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Oscillation Technique (FOT)
Number of subjects: 29
Study 9387947 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Expiratory Volume in one second (FEV1)
Number of subjects: 29
Study 9387947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of dry cold air (IHCA)
Number of subjects: 29
Study 7963780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodermoclysis (HDC)
Number of subjects: 100
Study 7963780 — intervention group
Group type: COMPARATOR
Intervention: No Hypodermoclysis (Control)
Number of subjects: 100
Study 3298301 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenge treatment
Number of subjects: 0
Study 3298301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium lactate tablets)
Number of subjects: 0
Study 29276123 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-Stabilized (PS) device
Number of subjects: 111
Study 29276123 — intervention group
Group type: COMPARATOR
Intervention: Condylar-Stabilized (CS) device
Number of subjects: 111
Study 27983687 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole oat flour (48 g)
Number of subjects: 13
Study 27983687 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole barley flour (48 g)
Number of subjects: 13
Study 27983687 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat flour plus cellulose (control)
Number of subjects: 13
Study 24034670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% Magnolia extract
Number of subjects: 94
Study 24034670 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 94
Study 22936658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy (10 mg or 15 mg)
Number of subjects: 39
Study 22936658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) with lenalidomide and rhu-EPO (40,000 U/wk)
Number of subjects: 39
Study 20077491 — intervention group
Group type: EXPERIMENTAL
Intervention: Stokes polarimetry imaging (SPI) system with varying incident polarization angles (IPA)
Number of subjects: 0
Study 20077491 — intervention group
Group type: COMPARATOR
Intervention: Dermoscopy and histology images
Number of subjects: 0
Study 18079083 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc dietary recommendations derived from factorial calculations
Number of subjects: 0
Study 15699058 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured warm‐up programme
Number of subjects: 1837
Study 15699058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1837
Study 12848631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg b.d.) + Amoxicillin (1000 mg b.d.) (RA group)
Number of subjects: 123
Study 12848631 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (10 mg b.d.) + Amoxicillin (750 mg twice b.d.) + Metronidazole (250 mg b.d.) (RAM group)
Number of subjects: 123
Study 10641899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intervention
Number of subjects: 0
Study 8963958 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemically effective dose of AII
Number of subjects: 8
Study 8963958 — intervention group
Group type: COMPARATOR
Intervention: Systemically ineffective dose of AII
Number of subjects: 8
Study 1390493 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of a preservative‐free aqueous solution of gentamicin
Number of subjects: 75
Study 1390493 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin containing sodium metabisulphite and disodium edetate as preservatives
Number of subjects: 75
Study 1390493 — intervention group
Group type: COMPARATOR
Intervention: No subconjunctival injection (Control Group)
Number of subjects: 75
Study 3924286 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey in oral rehydration solution
Number of subjects: 0
Study 29449329 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin‐laropiprant
Number of subjects: 3978
Study 29449329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3978
Study 27503091 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400 mg/day)
Number of subjects: 218
Study 27503091 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 218
Study 27503091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 23647356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine digluconate gel (CHX)
Number of subjects: 69
Study 23647356 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (Ca(OH)2)
Number of subjects: 69
Study 23647356 — intervention group
Group type: COMPARATOR
Intervention: Chemomechanical preparation with 3% sodium hypochlorite (NaOCl)
Number of subjects: 69
Study 22882916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate alone (1 mg; one dose before and two doses after biopsy)
Number of subjects: 367
Study 22882916 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate + ciprofloxacin (250 mg; one dose before and two doses after biopsy)
Number of subjects: 367
Study 19928700 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral rectus recession (7.0 to 7.5 mm for 15 to 20 PD and 8.0 to 8.5 mm for 21 to 25 PD)
Number of subjects: 20
Study 19928700 — intervention group
Group type: COMPARATOR
Intervention: Bilateral rectus recession (5.0 to 5.5 mm for 15 to 20 PD and 6.0 to 6.5 mm for 21 to 25 PD)
Number of subjects: 20
Study 19025274 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention (telephone counseling and tailored newsletters)
Number of subjects: 320
Study 19025274 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention
Number of subjects: 320
Study 19025274 — intervention group
Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 320
Study 16024926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose citric acid-based UBT at 14 days after triple therapy
Number of subjects: 233
Study 16024926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose citric acid-based UBT at 7 days after triple therapy
Number of subjects: 233
Study 16024926 — intervention group
Group type: COMPARATOR
Intervention: Gold standard UBT at 6 weeks after therapy
Number of subjects: 233
Study 12601506 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 20
Study 12601506 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg
Number of subjects: 20
Study 12601506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12601506 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg plus Cyproheptadine 4 mg
Number of subjects: 20
Study 12601506 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg plus Cyproheptadine 4 mg
Number of subjects: 20
Study 10365576 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (interferon-alpha 2b) for 6 months
Number of subjects: 40
Study 10365576 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 8660081 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (10 g/day)
Number of subjects: 66
Study 8660081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 1826048 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOLADEX (3.6 mg every 28 days by subcutaneous injection)
Number of subjects: 67
Study 1826048 — intervention group
Group type: COMPARATOR
Intervention: DES (3 mg daily by oral administration)
Number of subjects: 67
Study 1826048 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOLADEX
Number of subjects: 67
Study 1826048 — intervention group
Group type: COMPARATOR
Intervention: ZOLADEX and DES
Number of subjects: 67
Study 7134228 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium oxide adsorbate vaccines (54, 108, and 216 IU/dose)
Number of subjects: 90
Study 7134228 — intervention group
Group type: COMPARATOR
Intervention: Fluid monovalent influenza A/New Jersey/8/76 vaccines (double the antigen content)
Number of subjects: 90
Study 7134228 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium oxide adsorbate vaccines
Number of subjects: 90
Study 30580144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempo of audible pedestrian signals (40 bpm, 60 bpm, 120 bpm)
Number of subjects: 217
Study 30580144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch of audible pedestrian signals (175 Hz, 350 Hz, 700 Hz)
Number of subjects: 217
Study 30580144 — intervention group
Group type: EXPERIMENTAL
Intervention: Real crossing scenario with different tempos
Number of subjects: 217
Study 29883653 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated titanium fasteners
Number of subjects: 50
Study 29883653 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand‐tied knots
Number of subjects: 50
Study 26739723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme integrated into stroke rehabilitation
Number of subjects: 78
Study 25147037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter patent foramen ovale (PFO) closure using the STARFlex device
Number of subjects: 909
Study 25147037 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 909
Study 25147037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 909
Study 25147037 — intervention group
Group type: EXPERIMENTAL
Intervention: Index TIA
Number of subjects: 909
Study 25147037 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of atrial fibrillation after study enrollment
Number of subjects: 909
Study 25147037 — intervention group
Group type: EXPERIMENTAL
Intervention: RoPE (Risk of Paradoxical Embolism) score ≤5
Number of subjects: 909
Study 22683038 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula containing lactose (9.6 g/100 kcal) and maltodextrin (1.6 g/100 kcal)
Number of subjects: 178
Study 22683038 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% lactose formula (11.2 g/100 kcal)
Number of subjects: 178
Study 20390984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for information
Number of subjects: 122
Study 20390984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for emotional support
Number of subjects: 122
Study 18537025 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12
Study 18537025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16029995 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 983
Study 16029995 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 983
Study 16029995 — intervention group
Group type: COMPARATOR
Intervention: Calcium-channel blockers (CCB)
Number of subjects: 983
Study 16029995 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan, ACE inhibitors, CCB
Number of subjects: 983
Study 12173199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine < 20 min
Number of subjects: 120
Study 12173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 20-40 min
Number of subjects: 120
Study 12173199 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine > 40 min
Number of subjects: 120
Study 10348261 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel with amifostine
Number of subjects: 0
Study 10348261 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel without amifostine
Number of subjects: 0
Study 8559949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation light treatment until late winter (n = 8)
Number of subjects: 20
Study 8559949 — intervention group
Group type: COMPARATOR
Intervention: Stopped light treatment early during winter (n = 6)
Number of subjects: 20
Study 8559949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation light treatment
Number of subjects: 20
Study 8559949 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid avoidant personality
Number of subjects: 20
Study 2706319 — intervention group
Group type: EXPERIMENTAL
Intervention: Research Suspension (RS)
Number of subjects: 24
Study 2706319 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketing Suspension (MS)
Number of subjects: 24
Study 2706319 — intervention group
Group type: COMPARATOR
Intervention: Reference Oral Solution (SOL)
Number of subjects: 24
Study 2706319 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (MS, RS, SOL)
Number of subjects: 24
Study 2706319 — intervention group
Group type: EXPERIMENTAL
Intervention: MS and RS
Number of subjects: 24
Study 29668611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needle
Number of subjects: 40
Study 29668611 — intervention group
Group type: COMPARATOR
Intervention: Sham intradermal needle
Number of subjects: 40
Study 28807667 — intervention group
Group type: EXPERIMENTAL
Intervention: C-82
Number of subjects: 0
Study 28807667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25892575 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 62
Study 25892575 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 62